23:00 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies identified an inhibitor of the transmembrane domain of p75 NTR that could help treat melanoma. Screening of a compound library in a binding assay in bacteria expressing the...
20:27 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

Levicept begins Phase I of fusion protein for chronic pain

Levicept Ltd. (Sandwich, U.K.) began a Phase I trial to evaluate single ascending doses of its chronic pain candidate IV LEVI-04 (p75NTR-Fc) in healthy volunteers and in patients with pain due to osteoarthritis (OA) of...
22:17 , Sep 14, 2017 |  BC Extra  |  Clinical News

Levicept begins Phase I of fusion protein for chronic pain

Levicept Ltd. (Sandwich, U.K.) began a Phase I trial of its chronic pain candidate IV LEVI-04 (p75NTR-Fc) in healthy volunteers and in patients with pain due to osteoarthritis (OA) of the knee. LEVI-04 is a...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: p75 neurotrophin receptor (p75 NTR); nerve growth factor (NGF)

Ophthalmic disease INDICATION: Diabetic retinopathy; ophthalmic Mouse studies suggest inhibiting p75 NTR or the precursor form of NGF could help treat diabetic retinopathy and other types of retinopathy. In a mouse model of diabetic retinopathy, intravitreal injection...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Forkhead box A1 (FOXA1); FOXA2; FOXA3; GATA binding protein 4 (GATA4); HNF1 homeobox A (HNF1A); hepatocyte nuclear factor 4 α (HNF4A; TCF) FOXA3,

Hepatic disease INDICATION: Liver fibrosis Mouse studies suggest in vivo reprogramming of liver myofibroblasts into hepatocyte-like cells could help treat liver fibrosis. In a mouse model of the disease, in vivo transduction of myofibroblasts with six adeno-associated...
08:00 , Feb 8, 2016 |  BioCentury  |  Finance

Asset renaissance

The former life sciences team from Index Ventures has set up shop as Medicxi Ventures with a heavily oversubscribed new fund, and an investment model that has so far scored it a 100% success rate...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Engineered diatom-based biosilica particles for delivery of chemotherapeutics

Drug delivery TECHNOLOGY: Nanoparticles Diatom-based biosilica nanoparticles could be used to deliver chemotherapies to tumors. The nanoparticles were created by incorporating a recombinant IgG-binding domain into the diatom's genome, labelling the diatom's biosilica wall with an antibody...
01:42 , Oct 8, 2014 |  BC Extra  |  Financial News

Levicept raises L10M series A

Levicept Ltd. (Sandwich, U.K.) raised L10 million ($16 million) in a series A round with Advent Life Sciences, Gilde Healthcare and Index Ventures. The biotech's LEVI-04 ( p75NTR-Fc) is in preclinical development to treat chronic...
07:00 , Sep 15, 2014 |  BioCentury  |  Emerging Company Profile

Levicept: Modulating NGF

Levicept Ltd.'s p75NTR-Fc could provide the analgesic effect of nerve growth factor inhibitors to treat pain in osteoarthritis without the side effects that have sidelined the class in recent years. This potential made Levicept the...
07:00 , Sep 1, 2014 |  BioCentury  |  Finance

Nurturing killer seeds

Index Ventures is not the first VC to operate an incubator that conducts killer experiments on seed projects. But what could set the "Index Nursery" apart is the firm's intention to publicize its failures along...